文章：

DOK家族适配器在急性髓性白血病中的预后作用

Prognostic role of DOK family adapters in acute myeloid leukemia 

原文发布日期：2018-10-22 

英文摘要：

Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disease. Gene mutational and expressional profile can aid the identification of different prognostic subgroups. Downstream of tyrosine kinase (DOK) proteins are a multigenic family of adaptors; some of them are key negative regulators of immune cell signaling. However, the expression and clinical implication of DOK family in AML has rarely been investigated. A total of 155 AML patients with DOK family (DOK1-7) expression data from The Cancer Genome Atlas database were enrolled in the study. In patients who only received chemotherapy, those with high expressions of DOK4 or DOK5 had significantly shorter EFS and OS than patients with low expressions (all P < 0.001), whereas high DOK7 expressers had longer EFS and OS than the low expressers (all P < 0.05). In patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, all DOK members had no impact on EFS and OS. Multivariate analysis confirmed that high DOK5 expression was an independent risk factor for EFS and OS in untransplanted patients (all P < 0.05). Our study suggests that in AML, high expressions of DOK4 and DOK5 are adverse prognostic factors, high DOK7 expression is a good prognostic factor, but their effects can be overcome by allo-HSCT. 

摘要翻译： 

急性髓系白血病（AML）是一种遗传和临床异质性性疾病。基因突变和表达谱有助于识别不同的预后亚组。酪氨酸激酶下游（DOK）蛋白是一个多基因衔接蛋白家族，其中部分成员是免疫细胞信号传导的关键负向调控因子。然而，DOK家族在AML中的表达及临床意义尚未得到充分研究。本研究从癌症基因组图谱数据库中纳入155例具有DOK家族（DOK1-7）表达数据的AML患者。在仅接受化疗的患者中，DOK4或DOK5高表达患者的总生存期（OS）和无事件生存期（EFS）均显著短于低表达患者（均P<0.001），而DOK7高表达患者的EFS和OS均长于低表达患者（均P<0.05）。在接受异基因造血干细胞移植（allo-HSCT）的患者中，所有DOK家族成员对EFS和OS均无影响。多因素分析证实，在未移植患者中，DOK5高表达是EFS和OS的独立危险因素（均P<0.05）。本研究提示，在AML中DOK4和DOK5高表达是不良预后因素，DOK7高表达是良好预后因素，但这些效应可通过allo-HSCT克服。

原文链接：

Prognostic role of DOK family adapters in acute myeloid leukemia